ArticleFrontiers in neurology2025
Biomarkers and therapeutic targets in early Alzheimer's disease: an Olink proteomics study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to analyze differential expression of inflammation-related proteins in plasma from patients with mild cognitive impairment (MCI) and early-stage Alzheimer's disease (AD), for exploring potential biomarkers and therapeutic targets for AD, providing new possibilities for the early diagnosis of AD and the theoretical basis for the subsequent targeted therapy. Participants and methods: The study included 30 adults: 10 healthy control subjects (HC group), 10 patients with AD [AD group, positron emission tomography (PET)-confirmed] and 10 with MCI (MCI group, PET negative). We carried out Proximity Extension Assay (PEA) on 92 inflammation-related proteins in the plasma samples of these 30 participants by using the Olink proteomics technology. Subsequently, to evaluate the clinical translational potential of these Differentially Expressed Proteins (DEPs) as early AD biomarkers and their potential mechanisms of action, we performed Receiver Operator Characteristic (ROC) curve analysis and functional enrichment analysis on these proteins. Results: Compared with the HC group, uPA, CX3CL1, CDCP1, Flt3L, SCF and TWEAK proteins were significantly upregulated in AD group, with Area Under the ROC Curve (AUC) values of 0.96 ( Conclusion: Using Olink proteomics technology, this study identified several plasma inflammatory proteins associated with AD, which were proposed as potential biomarkers for early diagnosis. While these findings provided novel insights into early AD screening and molecular mechanisms, and suggested possible therapeutic targets, several limitations were noted. The study's modest sample size and cross-sectional design limited the ability to assess dynamic changes in these biomarkers during disease progression. Future large-scale longitudinal studies should validate their clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.